N-butyl-2-cyanoacrylate
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07086482 | Aug 2025 → Mar 2026 overdue | — | Beirut Arab University | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07132541 | Aug 2025 → Nov 2026 expected | ampulla of vater cancer, malignant pancreatic neoplasm | Minia University | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07230509 | Dec 2025 → Dec 2027 expected | ampulla of vater cancer, malignant pancreatic neoplasm | Minia University | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07155525 | Sep 2025 → Sep 2028 expected | cholangiocarcinoma, pancreatic ductal adenocarcinoma, periampullary adenocarcinoma | Minia University | Recruiting | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 3 | NCT06106971 Comparator | Jun 2018 → Jun 2025 | liver disorder, varicose disease | Kaohsiung Veterans General Hospital. | Unknown | No outcome recorded |
| Phase 3 | NCT03388125 Comparator | Jan 2016 → Aug 2017 | esophageal varices with bleeding | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT01717612 Comparator | Oct 2012 → Apr 2016 | esophageal varices, gastric ulcer | National Science and Technology Council, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT00799851 Comparator | Nov 2004 → May 2007 | liver disorder | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT02468180 Comparator | Jun 2015 → Jul 2022 | — | West China Hospital | Unknown | No outcome recorded |
| — | NCT02468167 Comparator | Jun 2015 → Jul 2020 | — | West China Hospital | Unknown | No outcome recorded |
| — | NCT02468206 Comparator | Jun 2015 → Feb 2018 | — | West China Hospital | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-Butyl-2 Cyanoacrylate | “the injected agents consisted of n-butyl-2-cyanoacrylate (Histoacryl; B.Braun, Melsungen AG, Germany) 0.5ml mixed with 1.5 ml Lipiodol ultra-fluide (Guerbet, Bois Cedex, France).” NCT01717612 ↗10“Endoscopic injection sclerotherapy versus N-Butyl-2 Cyanoacrylate injection in the management of actively bleeding esophageal varices: a randomized controlled trial.” PMID 30717684 ↗ Feb 2019 “CI group received intravariceal injections of 0.5 ml of N-butyl-2-cyanoacrylate (Histoacryl®) diluted in 0.5 ml of Lipiodol (Lipiodol®).” NCT00799851 ↗ “Injection of Histoacryl® (n-butyl-2-cyanoacrylate) mixed with Lipiodol® (1:1 ratio) into the pancreatic parenchyma” NCT07230509 ↗ “Information of drug: N-butyl-2-cyanoacrylate Name: Histoacryl blue Manufacturer: Braun, Melsungen, Germany” NCT06106971 ↗ |
| Known as | Histoacryl | “the injected agents consisted of n-butyl-2-cyanoacrylate (Histoacryl; B.Braun, Melsungen AG, Germany) 0.5ml mixed with 1.5 ml Lipiodol ultra-fluide (Guerbet, Bois Cedex, France).” NCT01717612 ↗2“CI group received intravariceal injections of 0.5 ml of N-butyl-2-cyanoacrylate (Histoacryl®) diluted in 0.5 ml of Lipiodol (Lipiodol®).” NCT00799851 ↗ “Injection of Histoacryl® (n-butyl-2-cyanoacrylate) mixed with Lipiodol® (1:1 ratio) into the pancreatic parenchyma” NCT07230509 ↗ |
| Known as | Histoacryl blue | “N-butyl-2-cyanoacrylate Name: Histoacryl blue Manufacturer: Braun, Melsungen, Germany” NCT06106971 ↗ |
| Known as | PeriAcryl | “The goal of this clinical trial is to learn if the use of cyanoacrylate glue (PeriAcryl) is effective in healing of the palatal donor site in adults requiring a free gingival graft.” NCT07086482 ↗ |
| Modality | Other / unclassified | “N-butyl-2-cyanoacrylate is a biodegradable tissue adhesive” NCT07155525 ↗ |
| Route | Other | “CI group received intravariceal injections” NCT00799851 ↗ |